S&P 500   3,758.48 (+2.18%)
DOW   30,089.01 (+2.03%)
QQQ   280.87 (+2.68%)
AAPL   144.78 (+1.64%)
MSFT   247.86 (+2.96%)
META   140.71 (+1.52%)
GOOGL   101.15 (+2.54%)
AMZN   121.31 (+4.69%)
TSLA   245.96 (+1.47%)
NVDA   130.19 (+4.05%)
NIO   16.59 (+7.10%)
BABA   83.40 (+3.67%)
AMD   68.00 (+2.86%)
T   16.00 (+0.63%)
MU   54.40 (+5.18%)
CGC   3.12 (+7.22%)
F   12.23 (+6.63%)
GE   67.00 (+5.35%)
DIS   100.93 (+3.91%)
AMC   7.52 (+9.30%)
PYPL   92.29 (+5.86%)
PFE   44.41 (+0.61%)
NFLX   239.27 (+0.10%)
S&P 500   3,758.48 (+2.18%)
DOW   30,089.01 (+2.03%)
QQQ   280.87 (+2.68%)
AAPL   144.78 (+1.64%)
MSFT   247.86 (+2.96%)
META   140.71 (+1.52%)
GOOGL   101.15 (+2.54%)
AMZN   121.31 (+4.69%)
TSLA   245.96 (+1.47%)
NVDA   130.19 (+4.05%)
NIO   16.59 (+7.10%)
BABA   83.40 (+3.67%)
AMD   68.00 (+2.86%)
T   16.00 (+0.63%)
MU   54.40 (+5.18%)
CGC   3.12 (+7.22%)
F   12.23 (+6.63%)
GE   67.00 (+5.35%)
DIS   100.93 (+3.91%)
AMC   7.52 (+9.30%)
PYPL   92.29 (+5.86%)
PFE   44.41 (+0.61%)
NFLX   239.27 (+0.10%)
S&P 500   3,758.48 (+2.18%)
DOW   30,089.01 (+2.03%)
QQQ   280.87 (+2.68%)
AAPL   144.78 (+1.64%)
MSFT   247.86 (+2.96%)
META   140.71 (+1.52%)
GOOGL   101.15 (+2.54%)
AMZN   121.31 (+4.69%)
TSLA   245.96 (+1.47%)
NVDA   130.19 (+4.05%)
NIO   16.59 (+7.10%)
BABA   83.40 (+3.67%)
AMD   68.00 (+2.86%)
T   16.00 (+0.63%)
MU   54.40 (+5.18%)
CGC   3.12 (+7.22%)
F   12.23 (+6.63%)
GE   67.00 (+5.35%)
DIS   100.93 (+3.91%)
AMC   7.52 (+9.30%)
PYPL   92.29 (+5.86%)
PFE   44.41 (+0.61%)
NFLX   239.27 (+0.10%)
S&P 500   3,758.48 (+2.18%)
DOW   30,089.01 (+2.03%)
QQQ   280.87 (+2.68%)
AAPL   144.78 (+1.64%)
MSFT   247.86 (+2.96%)
META   140.71 (+1.52%)
GOOGL   101.15 (+2.54%)
AMZN   121.31 (+4.69%)
TSLA   245.96 (+1.47%)
NVDA   130.19 (+4.05%)
NIO   16.59 (+7.10%)
BABA   83.40 (+3.67%)
AMD   68.00 (+2.86%)
T   16.00 (+0.63%)
MU   54.40 (+5.18%)
CGC   3.12 (+7.22%)
F   12.23 (+6.63%)
GE   67.00 (+5.35%)
DIS   100.93 (+3.91%)
AMC   7.52 (+9.30%)
PYPL   92.29 (+5.86%)
PFE   44.41 (+0.61%)
NFLX   239.27 (+0.10%)
NASDAQ:KPRX

Kiora Pharmaceuticals - KPRX Stock Forecast, Price & News

$7.70
+0.59 (+8.30%)
(As of 10/4/2022 01:08 PM ET)
Add
Compare
Today's Range
$7.50
$8.29
50-Day Range
$4.99
$264.00
52-Week Range
$4.86
$87.60
Volume
5,012 shs
Average Volume
318,793 shs
Market Capitalization
$7.08 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$70.00

Kiora Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
796.3% Upside
$70.00 Price Target
Short Interest
Healthy
641.30% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.05mentions of Kiora Pharmaceuticals in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($17.60) to ($9.60) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.21 out of 5 stars

KPRX stock logo

About Kiora Pharmaceuticals (NASDAQ:KPRX) Stock

Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1 clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, as well as for treating non-infectious posterior uveitis; and KIO-201, an eye drop, which is in Phase 3 clinical trial for treating patients undergoing PRK surgery for corneal wound repair after refractive surgery. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Salt Lake City, Utah.

Receive KPRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kiora Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

KPRX Stock News Headlines

Kiora Pharmaceuticals to Implement 1-for-40 Reverse Split
KPRX: What a difference a year makes!
See More Headlines
Receive KPRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kiora Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

KPRX Company Calendar

Last Earnings
7/08/2022
Today
10/04/2022
Next Earnings (Estimated)
11/21/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:KPRX
Fax
N/A
Employees
14
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$70.00
High Stock Price Forecast
$100.00
Low Stock Price Forecast
$40.00
Forecasted Upside/Downside
+809.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Net Income
$-13,770,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$10,000.00
Book Value
$46.09 per share

Miscellaneous

Free Float
916,000
Market Cap
$7.08 million
Optionable
Not Optionable
Beta
0.36

Key Executives

  • Dr. Brian M. Strem Ph.D. (Age 43)
    Pres, CEO, Principal Financial & Accounting Officer and Director
    Comp: $383.82k
  • Dr. Eric J. Daniels M.B.A. (Age 49)
    M.D., Chief Devel. Officer
  • Dr. Stefan Sperl Ph.D.
    Exec. VP of CMC & Operations
  • Dr. MaryJane Rafii Ph.D.
    Consultant













KPRX Stock - Frequently Asked Questions

Should I buy or sell Kiora Pharmaceuticals stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kiora Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" KPRX shares.
View KPRX analyst ratings
or view top-rated stocks.

What is Kiora Pharmaceuticals' stock price forecast for 2022?

3 brokers have issued 1 year target prices for Kiora Pharmaceuticals' shares. Their KPRX share price forecasts range from $40.00 to $100.00. On average, they expect the company's share price to reach $70.00 in the next year. This suggests a possible upside of 884.5% from the stock's current price.
View analysts price targets for KPRX
or view top-rated stocks among Wall Street analysts.

How have KPRX shares performed in 2022?

Kiora Pharmaceuticals' stock was trading at $60.40 at the beginning of the year. Since then, KPRX stock has decreased by 88.2% and is now trading at $7.11.
View the best growth stocks for 2022 here
.

When is Kiora Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 21st 2022.
View our KPRX earnings forecast
.

How were Kiora Pharmaceuticals' earnings last quarter?

Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) posted its quarterly earnings data on Friday, July, 8th. The company reported ($10.80) earnings per share (EPS) for the quarter.

When did Kiora Pharmaceuticals' stock split?

Shares of Kiora Pharmaceuticals reverse split before market open on Tuesday, September 27th 2022. The 1-40 reverse split was announced on Tuesday, September 27th 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, September 27th 2022. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

What is Kiora Pharmaceuticals' stock symbol?

Kiora Pharmaceuticals trades on the NASDAQ under the ticker symbol "KPRX."

How do I buy shares of Kiora Pharmaceuticals?

Shares of KPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Kiora Pharmaceuticals' stock price today?

One share of KPRX stock can currently be purchased for approximately $7.11.

How much money does Kiora Pharmaceuticals make?

Kiora Pharmaceuticals (NASDAQ:KPRX) has a market capitalization of $6.53 million and generates $10,000.00 in revenue each year. The company earns $-13,770,000.00 in net income (profit) each year or ($60.80) on an earnings per share basis.

How can I contact Kiora Pharmaceuticals?

Kiora Pharmaceuticals' mailing address is 271 Waverley Oaks Rd Ste 108, Waltham, Massachusetts 02452-8475. The official website for the company is eyegatepharma.com. The company can be reached via phone at (781) 788-8869 or via email at cdavis@lifesciadvisors.com.

This page (NASDAQ:KPRX) was last updated on 10/4/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.